Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. Show more

1280 Rancho Conejo Blvd, Thousand Oaks, CA, 91320, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

30.28M

52 Wk Range

$3.93 - $19.14

Previous Close

$4.20

Open

$4.15

Volume

41,205

Day Range

$4.03 - $4.29

Enterprise Value

97.04M

Cash

13.71M

Avg Qtr Burn

-9.787M

Insider Ownership

20.58%

Institutional Own.

47.70%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Tabelecleucel (tab-cel® or Ebvallo™) Details Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD)	BLA FDA meeting	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ATA3219 Details Non-Hodgkin lymphoma, Blood cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ATA188 Details Multiple sclerosis, Epstein-Barr virus	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ATA3219 Details Systemic lupus erythematosus, Lupus nephritis, Autoimmune disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.